#1 Clinical Trials Search in Europe

Pentixafor

Pentixafor is an innovative drug being studied in clinical trials for its potential in diagnosing and treating various types of cancer. This radioactive tracer targets a specific protein called CXCR4, which is found in high levels in many cancer cells. By attaching to CXCR4, Pentixafor allows doctors to visualize cancer locations in the body using PET scans. Researchers are investigating how Pentixafor compares to current imaging techniques and whether it can improve cancer detection and monitoring of treatment responses.

Table of Contents

What is PENTIXAFOR?

PENTIXAFOR is a new imaging agent being studied for use in diagnosing and evaluating certain types of cancer[1]. It is not a treatment drug, but rather a substance that helps doctors see cancer cells more clearly during a special type of scan called PET (Positron Emission Tomography). PENTIXAFOR is also known by its chemical name, [68Ga]Ga-Pentixafor[7].

How Does PENTIXAFOR Work?

PENTIXAFOR works by targeting a specific protein called CXCR4, which is found in high amounts on the surface of many cancer cells[1]. When PENTIXAFOR is injected into the body, it attaches to these CXCR4 proteins. The PENTIXAFOR is labeled with a small amount of radioactive material (gallium-68) that can be detected by a PET scanner. This allows doctors to see where the cancer cells are located in the body[2].

What Conditions is PENTIXAFOR Being Studied For?

PENTIXAFOR is being investigated for use in several types of cancer and blood disorders, including:

  • Multiple Myeloma: A type of blood cancer that affects plasma cells in the bone marrow[6]
  • Lymphoma: Cancer that starts in cells of the lymph system[2]
  • Neuroendocrine Tumors: Rare tumors that can occur in various parts of the body[1]
  • Thymoma: A tumor of the thymus gland[3]
  • Leukemia: Cancer of blood-forming tissues[4]
  • Adrenal Gland Disorders: Such as conditions causing excess hormone production[5]

The PENTIXAFOR Imaging Procedure

The PENTIXAFOR imaging procedure typically involves the following steps:

  1. A small amount of PENTIXAFOR is injected into a vein, usually in the arm[2].
  2. The patient waits for about 60 minutes to allow the PENTIXAFOR to circulate through the body and attach to cancer cells[7].
  3. The patient lies still on a bed that moves through a PET scanner, which takes images of the inside of the body[1].
  4. The scan usually takes between 45 to 90 minutes[1].

Potential Benefits of PENTIXAFOR Imaging

Researchers are studying PENTIXAFOR because it may offer several advantages over current imaging techniques:

  • It may be more sensitive in detecting certain types of cancer, especially those that don’t show up well on standard PET scans using a different tracer called FDG[8].
  • It could help doctors more accurately determine how far a cancer has spread (staging)[9].
  • It might be useful in detecting minimal residual disease (small amounts of cancer cells remaining after treatment)[9].
  • It could potentially help predict how a patient will respond to certain treatments[7].

Current Research and Clinical Trials

PENTIXAFOR is still considered an experimental imaging agent. It is being studied in clinical trials to determine its effectiveness and safety. These trials are comparing PENTIXAFOR PET scans to other imaging techniques and evaluating how well it can detect different types of cancer[6][8].

Some studies are also looking at how PENTIXAFOR imaging results compare to other tests, such as bone marrow biopsies or blood tests for minimal residual disease[7].

Safety and Side Effects

As PENTIXAFOR is still being studied, information about its safety and potential side effects is limited. However, the amount of radioactive material used is very small, and the radiation exposure is generally considered low[1].

In clinical trials, patients are monitored for any adverse reactions for about an hour after receiving the PENTIXAFOR injection[7]. Vital signs such as heart rate, blood pressure, and breathing rate are checked before and after the procedure[7].

It’s important to note that PENTIXAFOR is not a treatment itself, but a diagnostic tool. It does not treat cancer or cause any therapeutic effects[1].

Aspect Details
Primary Use Diagnostic imaging for various cancers
Mechanism Targets CXCR4 protein on cancer cells
Administration Intravenous injection before PET scan
Cancer Types Studied Multiple myeloma, lymphoma, neuroendocrine tumors, adrenal tumors
Potential Benefits Improved cancer detection and treatment monitoring
Current Status In clinical trials, not yet approved for general use
Safety Profile Generally well-tolerated, further research ongoing

FAQ

  • What types of cancer is Pentixafor being studied for? Pentixafor is being investigated for several types of cancer, including multiple myeloma, lymphoma, neuroendocrine tumors, and adrenal gland tumors. It shows promise in detecting cancers that may be difficult to image with current techniques.
  • How does Pentixafor work? Pentixafor is a radioactive tracer that binds to a protein called CXCR4, which is found in high levels on many cancer cells. When injected into the body, it attaches to these proteins, allowing cancer locations to be visualized using PET scans.
  • What are the potential benefits of using Pentixafor? Pentixafor may provide more accurate imaging of certain cancers compared to current techniques. This could lead to improved diagnosis, better monitoring of treatment responses, and potentially guide more targeted treatments in the future.
  • Are there any risks associated with Pentixafor? As with any new drug, researchers are carefully monitoring for potential side effects. The radiation exposure from the PET scan is generally low. So far, Pentixafor appears to be well-tolerated, but more research is needed to fully understand its safety profile.
  • How is Pentixafor administered in clinical trials? In most trials, Pentixafor is given as an intravenous injection about an hour before a PET scan is performed. The exact dose can vary between studies but is typically in the range of 2-5 mCi (millicuries) of the radioactive tracer.

Ongoing Clinical Trials on Pentixafor

  • Study of [68Ga]Ga-PentixaFor PET-CT Imaging in Patients with Metastatic Triple-Negative Breast Cancer

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study Comparing [68Ga]Ga-PentixaFor PET/CT and AVS for Diagnosing Primary Aldosteronism in Patients with Hypertension

    Recruiting

    4 1 1
    Investigated diseases:
    Investigated drugs:
    The Netherlands

  • Study on the Safety and Effectiveness of [90Y]Y-PentixaTher in Patients with Recurrent or Resistant CNS Lymphoma

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Germany

  • Study on [68Ga]Ga-PentixaFor PET Imaging for Better Risk and Disease Assessment in Patients with Multiple Myeloma

    Recruiting

    1 1 1
    Investigated drugs:
    Belgium The Netherlands

  • A Study Testing the Accuracy of 68Ga-Pentixafor PET/CT Imaging in Patients with Cardiac Sarcoidosis

    Not yet recruiting

    2 1 1
    Investigated drugs:
    The Netherlands

  • Study of [90Y]Y-PentixaTher and [68Ga]Ga-PentixaFor in patients with advanced Non-Hodgkin lymphomas: Evaluating radiopeptide-based imaging and therapy

    Not yet recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Germany

  • Study on [68Ga]Ga-PentixaFor PET Imaging for Identifying Unilateral Adrenal Aldosterone Secretion in Patients with Primary Aldosteronism

    Not recruiting

    4 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study on [68Ga]Ga-PentixaFor and [18F]FDG PET/CT Imaging for Staging Marginal Zone Lymphoma in Patients with Confirmed Diagnosis

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria France Germany Italy Spain

Glossary

  • PET scan: Positron Emission Tomography scan, an imaging test that uses a radioactive tracer to show how organs and tissues are functioning.
  • CXCR4: A protein found on the surface of some cells, including many cancer cells, that Pentixafor targets.
  • Radiotracer: A radioactive substance used in very small amounts to visualize internal body structures or processes.
  • Multiple myeloma: A cancer that forms in a type of white blood cell called a plasma cell.
  • Lymphoma: A type of cancer that begins in cells of the lymph system.
  • Neuroendocrine tumor: A rare tumor that begins in specialized cells called neuroendocrine cells.
  • SUV: Standardized Uptake Value, a measure of how much radiotracer is taken up by tissue in PET imaging.
  • Minimal residual disease: Small numbers of cancer cells that remain after treatment, often undetectable by standard tests.
  • Autologous stem cell transplantation: A procedure where a patient's own stem cells are collected, stored, and later given back to them after intensive therapy.
  • Pharmacokinetics: The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.

References

  1. https://clinicaltrials.gov/study/NCT03335670
  2. https://clinicaltrials.gov/study/NCT05093335
  3. https://clinicaltrials.gov/study/NCT06086327
  4. https://clinicaltrials.gov/study/NCT04504526
  5. https://clinicaltrials.gov/study/NCT06246357
  6. https://clinicaltrials.gov/study/NCT05364177
  7. https://clinicaltrials.eu/trial/study-on-68gaga-pentixafor-for-staging-and-evaluation-in-symptomatic-multiple-myeloma-patients-in-initial-treatment-or-relapse/
  8. https://clinicaltrials.gov/study/NCT05255926
  9. https://clinicaltrials.eu/trial/study-on-68gaga-pentixafor-for-detecting-multiple-myeloma-in-patients-under-66-eligible-for-stem-cell-transplantation/